Noribogaine

Overview

Noribogaine, also known as O-desmethylibogaine or 12-hydroxyibogamine, is the principal psychoactive metabolite of the oneirogen ibogaine. It may be involved in the potential antiaddictive effects of ibogaine and ibogaine-containing plant extracts, such as Tabernanthe iboga.[1–4] WP

The drug appears to have a complex mechanism of action, with many different observed activities. Some of its most potent actions is atypical κ-opioid receptor agonism and serotonin reuptake inhibition. Noribogaine has potent psychoplastogenic effects similarly to ibogaine.[5–14] WP

Noribogaine was first described in the scientific literature by 1958 and was first identified as a metabolite of ibogaine in 1995. It was first studied in humans in 2015.[15–18] WP

Uses, dosage and effects

Use and effects

Noribogaine is the major active metabolite of the oneirogen ibogaine and is thought to be primarily though not exclusively responsible for its effects. In contrast to ibogaine, noribogaine has been limitedly evaluated in humans. It was noted in 2007 that administration of noribogaine to humans had not yet been reported. In 2015 and 2016 however, two clinical studies of noribogaine were published. It was tested at relatively low doses of 3 to 180 mg in these studies. At these doses, no hallucinations, dream-like states, or other hallucinogenic effects were reported. Similarly, it produced no μ-opioid receptor agonistic pharmacodynamic effects, such as pupil constriction or analgesia. At higher doses, in the area of 400 to 1,000 mg or more, ibogaine has been reported to produce hallucinogenic effects.[6][17–21] WP

Risks and side effects

Adverse effects

Side effects of noribogaine include visual impairment (specifically increased light perception sensitivity), headache, nausea, vomiting, and QT prolongation.[17][18] WP

Interactions

Interactions

Noribogaine may interact with monoamine oxidase inhibitors (MAOIs), for instance due to its serotonin reuptake inhibition.[22] WP

Pharmacology

Pharmacodynamics

Noribogaine has been determined to act as a biased agonist of the κ-opioid receptor (KOR). It activates the G protein (GDP-GTP exchange) signaling pathway with 75% the efficacy of dynorphin A (EC₅₀ = 9 μM), but it is only 12% as efficacious at activating the β-arrestin pathway. With an IC₅₀ value of 1 μM, it can be regarded as an antagonist of the latter pathway.[10] WP

The β-arrestin signaling pathway is hypothesized to be responsible for the anxiogenic, dysphoric, or anhedonic effects of KOR activation. Attenuation of the β-arrestin pathway by noribogaine may be the reason for the absence of these aversive effects, while retaining analgesic and antiaddictive properties. This biased KOR activity makes it stand out from the other iboga alkaloids like ibogaine and the derivative 18-methoxycoronaridine (18-MC). Some other examples of atypical or biased KOR agonists include RB-64, 6'-GNTI, herkinorin, and nalfurafine.[10][23] WP

Noribogaine is a potent serotonin reuptake inhibitor, but does not affect the reuptake of dopamine. Unlike ibogaine, noribogaine does not bind to the sigma σ₂ receptor. Similarly to ibogaine, noribogaine acts as a weak NMDA receptor antagonist and binds to opioid receptors. It has greater affinity for each of the opioid receptors than does ibogaine. Noribogaine has been reported to be a low-efficacy serotonin releasing agent, although findings are conflicting and other studies have found that it is inactive as a serotonin releasing agent. As with ibogaine, noribogaine is inactive as an agonist of the serotonin 5-HT2A receptor.[11][12][24–31] WP

Noribogaine is a hERG inhibitor and appears at least as potent as ibogaine. The inhibition of the hERG potassium channel delays the repolarization of cardiac action potentials, resulting in QT interval prolongation and, subsequently, in arrhythmias and sudden cardiac arrest.[8][32] WP

Ibogaine and the structurally related hallucinogen harmaline are tremorigenic, whereas noribogaine is not or is much less so.[9][13][33][34] WP

Noribogaine, but not ibogaine, produces potent psychoplastogenic effects in vitro in preclinical research. This can be blocked by the serotonin 5-HT2A receptor antagonist ketanserin, by the mTOR inhibitor rapamycin, and by a TrkB antagonist.[12][13][14][29][35][36] WP

Pharmacokinetics

Noribogaine is highly lipophilic and shows high brain penetration in rodents.[5][8] WP

The elimination half-life of noribogaine is 24 to 50 hours.[5][17][18] WP

Research

Research

Noribogaine was first described in the scientific literature by at least 1958. It was first identified and described as a metabolite of ibogaine by 1995. The first evaluation of noribogaine in humans was published in 2015. In April 2026, the FDA allowed a Phase I clinical study of noribogaine hydrochloride to proceed in the United States.[15–18][28][34][37][38][39] WP

Chemistry

Formula

C19H24N2O PC

CAS number

481-88-9 PC

Molar mass (g/mol)

296.4 PC

IUPAC name (computed by PubChem)

(1R,15R,17S,18S)-17-ethyl-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4(9),5,7-tetraen-7-ol PC

SMILES

CC[C@H]1C[C@@H]2C[C@@H]3[C@H]1N(C2)CCC4=C3NC5=C4C=C(C=C5)O PC

InChIKey

RAUCDOKTMDOIPF-RYRUWHOVSA-N PC

PubChem CID

3083548

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Journal / agency Mash DC, Ameer B, Prou D, Howes JF, Maillet EL. Oral noribogaine shows high brain uptake and anti-withdrawal effects not associated with place preference in rodents. Journal of Psychopharmacology. Jul 2016. doi:10.1177/0269881116641331 · PMID 27044509
2. Journal / agency Glick SD, Maisonneuve IS. Mechanisms of antiaddictive actions of ibogaine. Annals of the New York Academy of Sciences. May 1998. doi:10.1111/j.1749-6632.1998.tb08237.x · PMID 9668680
3. Journal / agency Baumann MH, Pablo J, Ali SF, Rothman RB, Mash DC. Comparative neuropharmacology of ibogaine and its O-desmethyl metabolite, noribogaine. The Alkaloids. Chemistry and Biology. 2001. doi:10.1016/S0099-9598(01)56009-5 · PMID 11705118
4. Journal / agency Kubiliene A, Marksiene R, Kazlauskas S, Sadauskiene I, Razukas A, Ivanov L. Acute toxicity of ibogaine and noribogaine. Medicina. 2008. doi:10.3390/medicina44120123 · PMID 19142057
5. Journal / agency Wasko MJ, Witt-Enderby PA, Surratt CK. DARK Classics in Chemical Neuroscience: Ibogaine. ACS Chemical Neuroscience. October 2018. doi:10.1021/acschemneuro.8b00294 · PMID 30216039
6. Journal / agency Glick SD, Maisonneuve IM, Szumlinski KK. Mechanisms of action of ibogaine: Relevance to putative therapeutic effects and development of a safer iboga alkaloid congener. The Alkaloids. Chemistry and Biology. 2001. doi:10.1016/S0099-9598(01)56006-X · PMID 11705115
7. Journal / agency Glick SD, Maisonneuve IM, Szumlinski KK. 18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action. Annals of the New York Academy of Sciences. September 2000. doi:10.1111/j.1749-6632.2000.tb05211.x · PMID 11085336
8. Journal / agency Litjens RP, Brunt TM. How toxic is ibogaine?. Clinical Toxicology. 2016. doi:10.3109/15563650.2016.1138226 · PMID 26807959
9. Journal / agency Popik P, Layer RT, Skolnick P. 100 years of ibogaine: neurochemical and pharmacological actions of a putative anti-addictive drug. Pharmacological Reviews. June 1995. doi:10.1016/S0031-6997(25)06842-5 · PMID 7568327
10. Journal / agency Maillet EL, Milon N, Heghinian MD, Fishback J, Schürer SC, Garamszegi N, Mash DC. Noribogaine is a G-protein biased κ-opioid receptor agonist. Neuropharmacology. December 2015. doi:10.1016/j.neuropharm.2015.08.032 · PMID 26302653
11. Other Houck MM. Forensic Chemistry. 26 January 2015
12. Journal / agency Cameron LP, Tombari RJ, Lu J, Pell AJ, Hurley ZQ, Ehinger Y, Vargas MV, McCarroll MN, Taylor JC, Myers-Turnbull D, Liu T, Yaghoobi B, Laskowski LJ, Anderson EI, Zhang G, Viswanathan J, Brown BM, Tjia M, Dunlap LE, Rabow ZT, Fiehn O, Wulff H, McCorvy JD, Lein PJ, Kokel D, Ron D, Peters J, Zuo Y, Olson DE. A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature. January 2021. doi:10.1038/s41586-020-3008-z · PMID 33299186 · PMC7874389
13. Journal / agency Iyer RN, Favela D, Zhang G, Olson DE. The iboga enigma: the chemistry and neuropharmacology of iboga alkaloids and related analogs. Natural Product Reports. March 2021. doi:10.1039/d0np00033g · PMID 32794540 · PMC7882011
14. Journal / agency Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, Burbach KF, Soltanzadeh Zarandi S, Sood A, Paddy MR, Duim WC, Dennis MY, McAllister AK, Ori-McKenney KM, Gray JA, Olson DE. Psychedelics Promote Structural and Functional Neural Plasticity. Cell Rep. June 2018. doi:10.1016/j.celrep.2018.05.022 · PMID 29898390 · PMC6082376
15. Journal / agency Bartlett MF, Dickel DF, Taylor WI. The Alkaloids of Tabernanthe iboga. Part IV. 1 The Structures of Ibogamine, Ibogaine, Tabernanthine and Voacangine. Journal of the American Chemical Society. 1958. doi:10.1021/ja01534a036
16. Journal / agency Mash DC, Staley JK, Baumann MH, Rothman RB, Hearn WL. Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin. Life Sciences. 1995. doi:10.1016/0024-3205(95)00273-9 · PMID 7596224
17. Journal / agency Glue P, Lockhart M, Lam F, Hung N, Hung CT, Friedhoff L. Ascending-dose study of noribogaine in healthy volunteers: pharmacokinetics, pharmacodynamics, safety, and tolerability. Journal of Clinical Pharmacology. February 2015. doi:10.1002/jcph.404 · PMID 25279818
18. Journal / agency Glue P, Cape G, Tunnicliff D, Lockhart M, Lam F, Hung N, Hung CT, Harland S, Devane J, Crockett RS, Howes J, Darpo B, Zhou M, Weis H, Friedhoff L. Ascending Single-Dose, Double-Blind, Placebo-Controlled Safety Study of Noribogaine in Opioid-Dependent Patients. Clinical Pharmacology in Drug Development. November 2016. doi:10.1002/cpdd.254 · PMID 27870477
19. Other Alper, K. R., & Lotsof, H. S. (2007). The use of ibogaine in the treatment of addictions. Psychedelic Medicine: New Evidence for Hallucinogenic Substances as Treatments, 2, 43–66
20. Other CiteTiHKAL
21. Other Shulgin AT. Hallucinogens: A Forensic Drug Handbook. 2003
22. Journal / agency Rached G, Campana A, Fiani D, Nguyen C, Van den Eynde V, Gillman PK, Barnett BS. Safety and Efficacy of Monoamine Oxidase Inhibitors in Patients Who Use Psychoactive Substances: Potential Drug Interactions and Substance Use Disorder Treatment Data. CNS Drugs. January 2026. doi:10.1007/s40263-025-01256-7 · PMID 41546846
23. Journal / agency Ehrich JM, Messinger DI, Knakal CR, Kuhar JR, Schattauer SS, Bruchas MR, Zweifel LS, Kieffer BL, Phillips PE, Chavkin C. Kappa Opioid Receptor-Induced Aversion Requires p38 MAPK Activation in VTA Dopamine Neurons. The Journal of Neuroscience. Sep 2015. doi:10.1523/JNEUROSCI.2444-15.2015 · PMID 26377476 · PMC4571610
24. Journal / agency Baumann MH, Rothman RB, Pablo JP, Mash DC. In vivo neurobiological effects of ibogaine and its O-desmethyl metabolite, 12-hydroxyibogamine (noribogaine), in rats. The Journal of Pharmacology and Experimental Therapeutics. May 2001. doi:10.1016/S0022-3565(24)29567-7 · PMID 11303040
25. Other Gahlinger P. Illegal Drugs. 30 December 2003
26. Other Alper KR, Glick SD. Ibogaine: Proceedings from the First International Conference. 2001
27. Other Barceloux DG. Medical Toxicology of Drug Abuse: Synthesized Chemicals and Psychoactive Plants. 20 March 2012
28. Journal / agency Pearl SM, Herrick-Davis K, Teitler M, Glick SD. Radioligand-binding study of noribogaine, a likely metabolite of ibogaine. Brain Research. March 1995. doi:10.1016/0006-8993(95)00123-8 · PMID 7796150
29. Journal / agency Iyer RN, Favela D, Domokos A, Zhang G, Avanes AA, Carter SJ, Basargin AG, Davis AR, Tantillo DJ, Olson DE. Efficient and modular synthesis of ibogaine and related alkaloids. Nature Chemistry. March 2025. doi:10.1038/s41557-024-01714-7 · PMID 39915657 · PMC11952118
30. Other Hwu C, Havel V, Westergaard X, Mendieta AM, Serrano IC, Hwu J, Walther D, Lankri D, Selinger TL, He K, Liu R, Shern TP, Sun S, Ma B, González B, Goodman HJ, Sonders MS, Baumann MH, Carrera I, Sulzer D, Sames D. Deciphering Ibogaine's Matrix Pharmacology: Multiple Transporter Modulation at Serotonin Synapses. 10 March 2025
31. Journal / agency Havel V, Kruegel AC, Bechand B, McIntosh S, Stallings L, Hodges A, Wulf MG, Nelson M, Hunkele A, Ansonoff M, Pintar JE, Hwu C, Ople RS, Abi-Gerges N, Zaidi SA, Katritch V, Yang M, Javitch JA, Majumdar S, Hemby SE, Sames D. Oxa-Iboga alkaloids lack cardiac risk and disrupt opioid use in animal models. Nat Commun. September 2024. doi:10.1038/s41467-024-51856-y · PMID 39304653 · PMC11415492
32. Journal / agency Alper K, Bai R, Liu N, Fowler SJ, Huang XP, Priori SG, Ruan Y. hERG Blockade by Iboga Alkaloids. Cardiovascular Toxicology. Jan 2016. doi:10.1007/s12012-015-9311-5 · PMID 25636206
33. Journal / agency Baumann MH, Pablo JP, Ali SF, Rothman RB, Mash DC. Noribogaine (12-hydroxyibogamine): a biologically active metabolite of the antiaddictive drug ibogaine. Annals of the New York Academy of Sciences. September 2000. doi:10.1111/j.1749-6632.2000.tb05210.x · PMID 11085335
34. Journal / agency Zetler G, Singbartl G, Schlosser L. Cerebral pharmacokinetics of tremor-producing harmala and iboga alkaloids. Pharmacology. 1972. doi:10.1159/000136294 · PMID 5077309
35. Journal / agency Palhas M, Corne R, Mongeau R. Changing your mind: neuroplastic mechanisms underlying the therapeutic effect of psychedelics in depression, PTSD, and addiction. Prog Neuropsychopharmacol Biol Psychiatry. October 2025. doi:10.1016/j.pnpbp.2025.111533 · PMID 41130352
36. Journal / agency Ona G, Reverte I, Rossi GN, Dos Santos RG, Hallak JE, Colomina MT, Bouso JC. Main targets of ibogaine and noribogaine associated with its putative anti-addictive effects: A mechanistic overview. J Psychopharmacol. December 2023. doi:10.1177/02698811231200882 · PMID 37937505
37. Journal / agency Hearn WL, Pablo J, Hime GW, Mash DC. Identification and quantitation of ibogaine and an o-demethylated metabolite in brain and biological fluids using gas chromatography-mass spectrometry. Journal of Analytical Toxicology. October 1995. doi:10.1093/jat/19.6.427 · PMID 8926737
38. Journal / agency Rezvani AH, Mash DC, Hearn WL, Lee YW, Overstreet DH. Noribogaine, a primary Ibogaine metabolite, reduces alcohol intake in P and fawn-hooded rats. Alcohol: Clin. Exp. Res. 1995
39. Journal / agency FDA Accelerates Action on Treatments for Serious Mental Illness Following Executive Order. 2026-04-24

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.